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Abstract Omega-3 fatty acid products are available as
prescription formulations (icosapent ethyl, omega-3-acid
ethyl esters, omega-3-acid ethyl esters A, omega-3-car-
boxylic acids) and dietary supplements (predominantly fish
oils). Most dietary supplements and all but one prescription
formulation contain mixtures of the omega-3 fatty acids
eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA). Products containing both EPA and DHA may raise
low-density lipoprotein cholesterol (LDL-C). In clinical
trials, the EPA-only prescription product, icosapent ethyl,
did not raise LDL-C compared with placebo. To correct a
common misconception, it is important to note that omega-
3 fatty acid dietary supplements are not US FDA–approved
over-the-counter drugs and are not required to demonstrate
safety and efficacy prior to marketing. Conversely, pre-
scription products are supported by extensive clinical
safety and efficacy investigations required for FDA
approval and have active and ongoing safety monitoring
programs. While omega-3 fatty acid dietary supplements
may have a place in the supplementation of diet, they
generally contain lower levels of EPA and DHA than
prescription products and are not approved or intended to
treat disease. Perhaps due to the lack of regulation of
dietary supplements, EPA and DHA levels may vary
widely within and between brands, and products may also
contain unwanted cholesterol or fats or potentially harmful
components, including toxins and oxidized fatty acids.
Accordingly, omega-3 fatty acid dietary supplements
should not be substituted for prescription products.
Similarly, prescription products containing DHA and EPA
should not be substituted for the EPA-only prescription
product, as DHA may raise LDL-C and thereby complicate
the management of patients with dyslipidemia.
Key Points
Omega-3 products are available as dietary
supplements and prescription formulations; products
containing docosahexaenoic acid (DHA) may have
the unwanted effect of raising low-density
lipoprotein cholesterol (LDL-C).
Dietary supplements are not over-the-counter (OTC)
products, and efficacy, quality, and safety of omega-
3 dietary supplements are questionable because of a
lack of regulation and potential content variability;
currently, there are no approved OTC omega-3 fatty
acid products.
Omega-3 dietary supplements are not appropriate for
the treatment of disease and are not therapeutically
equivalent to, and should not be substituted for,
prescription omega-3 fatty acid products;
prescription products containing DHA should not be
substituted for icosapent ethyl (highly purified
eicosapentaenoic acid [EPA]).
1 Introduction
For more than 35 years, omega-3 fatty acids have been
thought to provide cardiovascular benefits, beginning with
epidemiologic studies linking high omega-3 fatty acid
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dietary intake with reduced rates of cardiovascular disease
in Greenland Inuits [1–3]. Subsequent diet-based studies
suggested that increased omega-3 fatty acid consumption
reduced cardiovascular mortality in high-risk (but not low-
risk) individuals [4]. Stemming from these and other
findings, numerous fish oil dietary supplements containing
omega-3 fatty acids have become commercially available.
Over the last decade, several prescription omega-3 fatty
acid products have been approved by the US FDA based on
clinical intervention trials. Dietary supplements of other
classes of omega-3 fatty acid products are widely available,
but there are no FDA-approved over-the-counter (OTC)
omega-3 fatty acid drugs. This article provides an overview
of the basic biochemistry and potential cardiovascular
benefits of omega-3 fatty acids and compares omega-3
fatty acid prescription products and fish oil dietary sup-
plements, highlighting key considerations for their clinical
use.
2 Overview of Fatty Acid Biochemistry
Fatty acids are carboxylic acids; they have a carboxyl
group (COOH) at one end, they contain long carbon chains,
and most have an even number of carbon atoms. The
nomenclature for fatty acids takes into account whether the
molecule contains double bonds: saturated fatty acids have
no double bonds (thus the carbon atoms are ‘‘saturated’’
with hydrogen), whereas polyunsaturated fatty acids have
multiple double bonds. The full name begins with the
number of carbon atoms, followed by the number of double
bonds. For those with double bonds, the location of the first
double bond (counting from the methyl [CH3] end) is also
defined in the nomenclature, using ‘‘n-x’’ or ‘‘omega-x’’ [5,
6]. As shown in Fig. 1, polyunsaturated fatty acids that
have the first double bond in the third position (counting
from the methyl end) belong to the n-3 (omega-3) family
and include a-linolenic acid (ALA; 18:3, n-3), eicosapen-
taenoic acid (EPA; 20:5, n-3), and docosahexaenoic acid
(DHA; 22:6, n-3); those that have the first double bond in
the sixth position (counting from the methyl end) belong to
the n-6 (omega-6) family and include linoleic acid (LA;
18:2, n-6) and arachidonic acid (AA; 20:4, n-6).
Some fatty acids are considered essential because they
are required for good health but cannot be synthesized in
sufficient quantities by the body and therefore must be
obtained in the diet. ALA and LA are essential fatty acids
and precursors of key n-3 and n-6 fatty acids [7, 8]. Certain
oils (e.g., flaxseed, canola) are high in ALA, which is a
precursor of the longer-chain omega-3 fatty acids, includ-
ing EPA and DHA (Fig. 1). However, the conversion of
ALA into EPA and DHA is not very efficient in humans
[8]. Fish are good sources of EPA and DHA because fish
consume algae that produce EPA and DHA [8] or are
predators of other fish that consume algae. While EPA and
DHA are structurally and chemically distinct, DHA can be
derived from EPA [7–9]. Other oils (e.g., corn, safflower,
sunflower) are high in the omega-6 fatty acid LA, which is
the precursor of AA.
Fatty acids are key components of both triglycerides and
membrane phospholipids; triglycerides contain a glycerol
backbone that is esterified to three fatty acids. Phospho-
lipids containing a glycerol backbone are known as phos-
phoglycerides and are similar to triglycerides, but one of
the three fatty acids is replaced by a phosphate group
(Fig. 2). When fatty acids are not attached to other mole-
cules, they are known as free fatty acids. Omega-3 and
omega-6 fatty acids are incorporated into membrane
phospholipids, where they alter the physical properties of
cellular membranes and serve as precursors for several
classes of lipid mediators [7, 8]. The relative amount, not
































Fig. 1 Structures of omega-3 fatty acids. Both omega-6 and omega-3
fatty acids are polyunsaturated fatty acids, meaning that the hydro-
carbon chain contains multiple double bonds. The naming convention
is [number of carbon atoms]:[number of double bonds], n- (or x)-
[position of first double bond starting from the methyl end of the
chain, shown in red]. Omega-3 fatty acids generally have anti-
inflammatory and anti-thrombotic properties, whereas omega-6 fatty
acids generally have pro-inflammatory and pro-thrombotic properties
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key, because EPA and DHA compete with AA for the
second carbon, or ‘‘sn-2,’’ position in membrane phos-
pholipids [7]. When cells are exposed to inflammatory
stimuli, the enzyme phospholipase A2 acts to release the
incorporated polyunsaturated fatty acids from the sn-2
position of the phospholipid. The fatty acids are then
converted by cyclooxygenase into eicosanoid-signaling
molecules [9]. AA is converted into eicosanoids that gen-
erally have pro-inflammatory or pro-thrombotic effects,
whereas those derived from EPA typically have anti-in-
flammatory or anti-thrombotic effects [6, 9].
3 Cardiovascular Benefits of Omega-3 Fatty Acids
The omega-3 fatty acids EPA and DHA are generally
effective in reducing triglycerides and non-high-density
lipoprotein cholesterol (non-HDL-C) in patients with
hypertriglyceridemia; these effects are observed with
monotherapy and when administered in combination with a
statin [10–16]. However, EPA and DHA may have differ-
ential effects on low-density lipoprotein cholesterol (LDL-
C). DHA may raise LDL-C, whereas EPA has a neutral
effect or may slightly lower LDL-C [17, 18]. The effect of
DHA on LDL-C may be attributed in part to findings that
DHA may downregulate the LDL receptor [19, 20].
The benefit of reducing triglycerides on cardiovascular
outcomes remains to be conclusively proven, but emerging
evidence from genetic studies suggests that triglycerides
and triglyceride-rich lipoproteins play a causal role in
coronary atherosclerosis [21–26]. In two independent
studies of large US and Danish cohorts, individuals with
life-long low triglycerides due to mutations in the
apolipoprotein C3 (APOC3) gene had approximately 40 %
lower coronary heart disease (CHD) risk than individuals
with normal APOC3 alleles [21, 22]. In the Danish cohort,
this association was attenuated by adjusting for non-fasting
triglycerides, implying that the effect of APOC3 on
Fig. 2 Omega-3 fatty acids are
components of triglycerides and
phospholipids, and may also be
found as free fatty acids. Star
indicates sn-2 position;
phospholipase A2 releases fatty
acids from the sn-2 position of
membrane phospholipids
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triglycerides was at least partially responsible for the
lowered CHD risk [23]. ApoC-III is a protein coded by the
APOC3 gene that is part of the very-low-density lipopro-
tein complex and inhibits lipases, thus decreasing the
uptake of triglyceride-rich lipoprotein particles [23]. More
recently, genetic studies have revealed that inactivating
mutations in the gene encoding ANGPTL4 (a regulatory
factor in triglyceride metabolism) are associated with lower
triglyceride levels and lower risk of coronary artery disease
[25, 26].
The potential cardiovascular benefits of omega-3 fatty
acids are not restricted to their effects on lipids. Omega-3
fatty acids, particularly EPA, have pleiotropic effects at
multiple steps involved in atherosclerosis [27, 28]. For
example, EPA has beneficial effects on endothelial func-
tion [29, 30] by improving the balance between the
vasodilator nitric oxide and damaging reactive oxygen
species [31]. EPA has been shown to have beneficial
effects on monocyte migration and subsequent differenti-
ation into macrophages and foam cells, which are key steps
in early atherosclerotic lesion development [32–35].
Atherosclerosis is a chronic inflammatory disease [36–38]
and EPA may reduce the components of inflammation via
beneficial effects on eicosanoids, as discussed earlier [6, 9],
and by altering pro-inflammatory cytokine levels [39, 40].
EPA has also been shown to reduce plaque volume and
carotid intima-media thickness, suggesting it may influence
plaque formation and progression [41–46]. Finally, the
omega-3 fatty acids reduce adenosine diphosphate–induced
platelet aggregation, suggesting the potential for limiting
thrombus formation following plaque rupture [47].
4 Prescription Omega-3 Fatty Acid Products
Several omega-3 fatty acid prescription products have
been approved by the FDA for use as an adjunct to diet
for reducing triglycerides in adults with severe hyper-
triglyceridemia (triglycerides C500 mg/dl) (Table 1).
These include products containing both EPA and DHA
(Lovaza [omega-3-acid ethyl esters], GlaxoSmithKline,
Research Triangle Park, NC, USA; Omtryg [omega-3-
acid ethyl esters A], Trygg Pharma, Inc, Arlington, VA,
USA; Epanova [omega-3-carboxylic acids], AstraZeneca
Pharmaceuticals, Wilmington, DE, USA; and generic
Lovaza formulations) [48–52]. Omega-3-acid ethyl esters
[48] and omega-3-acid ethyl esters A [49] contain omega-
3-acid ethyl esters, whereas the omega-3-carboxylic acids
product is a fish oil-derived mixture of polyunsaturated
free fatty acids, including omega-3 fatty acids, the most
abundant of which are EPA and DHA [13, 50, 53]. There
is one FDA-approved EPA-only product: a high-purity
formulation containing icosapent ethyl, the ethyl ester of
EPA (Vascepa, Amarin Pharma, Inc, Bedminster, NJ,
USA); it does not contain DHA or any other omega-3
fatty acid [54].
Table 1 US FDA-approved prescription omega-3 fatty acid products indicated as an adjunct to diet to reduce triglyceride levels in adult patients







Dosing/administration Adverse reactions in clinical trials
Vascepa Icosapent ethyl 1 g None 4 g/day (2 capsules bid) with food Arthralgia,b oropharyngeal pain
Lovazac Omega-3-acid ethyl
esters
*0.465 g *0.375 g 4 g/day (4 capsules od or 2








0.55 g 0.2 g 2 g or 4 g/day (2 or 4 capsules od).
In clinical trials, administration
took place without regard to
meals







*0.465 g *0.375 g 4 g/day (4 capsules od or 2
capsules bid) with food
Eructation,d dyspepsia,d taste
perversion,d constipation, GI
disorder, vomiting, increased ALT/
AST, pruritus, rash
ALT alanine aminotransferase, AST aspartate aminotransferase, bid twice daily, DHA docosahexaenoic acid, EPA eicosapentaenoic acid, GI
gastrointestinal, od once daily
a Per capsule
b Incidence C2 % and[placebo
c Generic formulations of Lovaza are available
d Incidence C3 % and[placebo
e Epanova is approved but not available at the time of the writing of this review
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The safety and lipid-lowering efficacy of the prescrip-
tion omega-3 fatty acid products have been evaluated in
randomized, blinded, placebo-controlled trials of patients
with very high baseline triglycerides (C500 mg/dl) (Fig. 3)
[10–13, 48–50, 54] and patients with residually high
triglycerides (C200 to\500 mg/dl) despite statin therapy
(Table 2) [14–16, 48]. In addition to the reductions in
triglycerides, non-HDL-C, and total cholesterol observed
across these clinical trials, it is notable that increases in
LDL-C compared with placebo were observed for trials of
products containing DHA and EPA but not for trials of the
EPA-only product, icosapent ethyl (Fig. 3; Table 2). Also
notable is the finding that higher baseline triglycerides
were generally associated with greater triglyceride reduc-
tions [12, 18, 55]. Thus, it is expected that the differences
in the magnitude of triglyceride reductions observed across
clinical trials of prescription omega-3 fatty acid products
shown in Table 2 and Fig. 3 are reflections of differences
in patient baseline triglycerides. All of the prescription
omega-3 fatty acid products have been generally well tol-
erated in clinical trials and have well-established safety and
tolerability profiles. The most common adverse events for
the prescription omega-3 fatty acid products are provided
in Table 1 [48–52, 54]. Notably, the most common adverse
events occurring with prescription products containing
DHA and EPA were predominantly gastrointestinal, but
not with the EPA-only product, icosapent ethyl (Table 1).
Use of products containing both DHA and EPA also
require periodic monitoring of LDL-C during therapy due
to the potential for increases in this lipid parameter, while
treatment with the EPA-only product, icosapent ethyl, has

























































Value (mg/dL) Lovaza Vascepa Omtryg Epanova
Fig. 3 Percentage change from baseline versus placebo in key lipid
parameters from clinical trials of prescription omega-3 fatty acid
products (4 g/day) in patients with very high triglycerides (C500 mg/
dl) [48–50, 54]. Upper limit for triglycerides was 2000 mg/dl in
studies of omega-3-acid ethyl esters, omega-3-carboxylic acids, and
icosapent ethyl and 1500 mg in the omega-3-acid ethyl esters A
study. Omega-3-acid ethyl esters values are based on pooled data
from two studies [10, 11] (6 and 16 weeks’ duration) as reported in
the omega-3-acid ethyl esters prescribing information [48]. Icosapent
ethyl data are from the MARINE (Multi-Center, Placebo-Controlled,
Randomized, Double-Blind, 12-Week Study with an Open-Label
Extension) study (12 weeks) [12]. Omega-3-acid ethyl esters A data
(12 weeks) have only been published in the product’s prescribing
information [49]. Omega-3-carboxylic acids data are from the
EVOLVE (Epanova for Lowering Very High Triglycerides) study
(12 weeks) [13]. Difference versus placebo: omega-3-acid ethyl
esters = omega-3-acid ethyl esters median % change—placebo
median % change; icosapent ethyl = median of [icosapent ethyl %
change—placebo % change] (Hodges–Lehmann estimate); omega-3-
acid ethyl esters A = Hodges–Lehmann median of all pairwise
differences from placebo; omega-3-carboxylic acids = median of
[omega-3-carboxylic acids % change—placebo % change] (Hodges–
Lehmann estimate). HDL-C high-density lipoprotein cholesterol,
LDL-C low-density lipoprotein cholesterol, TC total cholesterol, TG
triglycerides
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5 Omega-3 Fatty Acid Dietary Supplements
Several types of dietary supplements containing omega-3
fatty acids are available, including fish oils, krill oils, algal
oils, and plant oils (Table 3). Except for plant sources (e.g.,
soybeans, walnuts, and canola oil, which contain ALA), all
contain a mixture of EPA and DHA, but may also include
saturated fats, other lipids, and potentially harmful ingre-
dients [56–62]. These products are widely available in drug
and health food stores, with more than 300 ‘‘omega-3’’
products listed in the US National Institutes of Health
Dietary Supplement Label Database [63].
Although the widely available omega-3 fatty acid
dietary supplements can be obtained without a pre-
scription, it is important to understand that they are not
OTC drugs. It is a common misconception among
physicians, pharmacists, and patients that omega-3 fatty
acid dietary supplements are FDA-approved OTC drugs.
Table 2 Effects of omega-3 fatty acids (4 g/day) added to statin therapy on key lipid parameters in patients with high triglyceride levels at
baseline (C200 and\500 mg/dl)a



















Baseline level (mg/dl) 268 271 265 259 287 280
% change from baseline -30 -6 -18 ?6 -21 -8
% difference vs. placebo -23f (p\ 0.0001) -22f (p\ 0.0001) NR (p\ 0.001)
Total cholesterol
Baseline level (mg/dl) 184 184 167 168 178 174
% change from baseline -5 -2 -3 ?9 -4 ?0.5
% difference vs. placebo –3f (p\ 0.05) –12f (p\ 0.0001) NR (p\ 0.001)
Non-HDL-C
Baseline level (mg/dl) 137 141 128 128 139 135
% change from baseline -9 -2 -5 ?10 -7 -0.9
% difference vs. placebo -7f (p\ 0.0001) -14f (p\ 0.0001) NR (p\ 0.001)
LDL-C
Baseline level (mg/dl) 91 88 82 84 94 92
% change from baseline ?0.7 -3 ?2 ?9 ?1 ?1
% difference vs. placebo ?4f (p = 0.05) –6f (p = 0.0067) NR (NS)
HDL-C
Baseline level (mg/dl) 46 43 37 39 39 39
% change from baseline ?3 -1 -1 ?5 ?3 ?2
% difference vs. placebo ?5f (p\ 0.05) -5f (p = 0.0013) NR (NS)
COMBOS Combination of Prescription Omega-3 with Simvastatin study, ESPRIT Epanova Combined with a Statin in Patients with Hyper-
triglyceridemia to Reduce Non-HDL Cholesterol study, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol,
NCEP ATP III National Cholesterol Education Program Adult Treatment Panel III, NR not reported, NS not significant (p[ 0.05), TG
triglycerides
a Additional lipid inclusion criteria: COMBOS, mean LDL-C B10 % above NCEP ATP III goal; ANCHOR, LDL-C C40 and\100 mg/dl on
optimized statin therapy, with criteria later expanded to mean of 2 TG-qualifying values C185 mg/dl with at least 1 value C200 mg/dl and upper
limit of LDL-C B115 mg/dl; ESPRIT, LDL-C at B110 % of NCEP ATP III goal or on maximally tolerated statin dose
b In 2014, data regarding patients with TG levels 200–499 mg/dl was removed from the prescribing information
c Simvastatin 40 mg/dl
d Stable statin therapy with atorvastatin, rosuvastatin, or simvastatin
e Stable statin therapy with lovastatin, pravastatin, fluvastatin, simvastatin, atorvastatin, or rosuvastatin
f Difference vs. placebo: omega-3-acid ethyl esters = omega-3-acid ethyl esters median % change—placebo median % change; icosapent
ethyl = median of (icosapent ethyl % change—placebo % change) (Hodges–Lehmann estimate)
234 J. Fialkow
As per the Dietary Supplement Health and Education
Act (DSHEA) of 1994, dietary supplements are not
considered drugs for purposes of FDA regulation, and
therefore are not subject to the same regulatory oversight
as prescription or OTC drugs [64]. As such, dietary
supplements are not required to demonstrate safety prior
to marketing [65]. Moreover, dietary supplements do not
require pre-marketing approval from the FDA, and,
under the DSHEA of 1994, anything labeled as a dietary
supplement is assumed to be safe until proven otherwise.
Importantly, it has been suggested that physicians and
patients cannot be assured that dietary supplements are
safe without sweeping legal and regulatory changes [66].
No OTC omega-3 fatty acid products are currently
approved or available in the USA.
There are issues and concerns regarding the content,
quality, and purity of omega-3 fatty acid dietary supple-
ments. It is important to recognize that dietary supplements
do not always contain what is specified on their label and
may differ in EPA and DHA content from batch to batch
[62, 67–69]. For example, analytic studies have reported
actual EPA and DHA concentrations in dietary supple-
ments sold in the USA ranging from 51 to 124 % (EPA)
and from 61 to 153 % (DHA) of the amounts stated on the
product labels [62]. More recent studies have confirmed
these findings (range 66–184 % [EPA] and 62–184 %
[DHA] of the stated label amounts), with 74 % of sup-
plements tested containing less than 100 % of the stated
amounts and 16 % of supplements containing less than
80 % of the stated amounts [67]. In a recent study of fish
oil supplements marketed in New Zealand, two-thirds of
supplements tested contained less than 67 % of the stated
amounts of EPA and DHA, with 2 of 32 supplements
containing only one-third of the stated label amounts [68].
Supplements have also been reported to meet total
EPA ? DHA content claimed on the label but not stated
levels of individual components (i.e., lower EPA content
and higher DHA content than stated on the label) [69].
Regarding additional ingredients found in omega-3 fatty
acid dietary supplements, one study specifically testing the
contents found that half of the samples tested provided
30–50 % of recommended daily cholesterol intake at a
dose of 3.4 g EPA/DHA, and two-thirds of the products
provided at least 2.5 g of saturated fats [61]. Some omega-
3 fatty acid dietary supplements have also been found to be
highly oxidized. Omega-3 fatty acids are highly prone to
oxidation because of the double bonds within the fatty acid
chain, leaving fewer non-oxidized fatty acids for thera-
peutic benefit and replacing them with a complex mixture
of lipid peroxides and secondary oxidation products [68].
In product testing, only 8 % of fish oil supplements met all
international recommendations for levels of oxidation
markers, and the safety of these oxidation products has not
been well investigated [68, 70]. Testing of 171 Canadian
omega-3 fatty acid dietary supplements revealed that 50 %
of products failed at least one of the voluntary safety
standards recommended for product oxidation [71]. Recent
data have demonstrated that oxidation products found in
dietary supplements can interfere with the ability of
omega-3 fatty acids to inhibit human small, dense LDL
oxidation and hence may interfere with their potential
biological benefits [72]. A review of the literature found
that oxidized lipids can be absorbed and metabolized and
alter cholesterol metabolism in multiple models by
increasing cholesterol uptake by macrophages, decreasing
cholesterol re-uptake in the liver, and increasing total
cholesterol levels [73]. Oxidized lipids were also noted to
adversely affect markers of oxidative stress and to cause
pro-inflammatory effects in animal and human studies,
leading the authors of those studies to conclude that oxi-
dized lipids have the potential to increase the risk of
atherosclerosis and thrombosis [73]. Taken together, the
data on the purity and content of omega-3 fatty acid dietary
supplements coupled with the lack of regulation regarding
these products shed light upon the fact that omega-3 fatty
acid dietary supplements are not being adequately moni-
tored by manufacturers or government agencies.
In addition to all of the content variability and safety
issues discussed above, one further aspect hindering the
therapeutic use of omega-3 fatty acid dietary supplements
is that dietary supplements may require a high pill burden
to achieve the dose levels found in prescription products,
which in turn may adversely impact treatment adherence
[74, 75].
Table 3 Non-prescription omega-3 fatty acid products: dietary
supplements
Products More than 300 products available
Formulations Soft gels, liquids, powders, gummies
Sources Fish oils, krill oils, algal oils, plant oils
Omega-3 fatty acid
content and purity
Predominantly DHA ? EPA in varying
quantities; DHA may raise LDL-C levels
May contain inconsistent DHA/EPA levels
May contain saturated fat, cholesterol,
oxidation products, and/or other




Not required to demonstrate efficacy or
safety prior to marketing
Should not be substituted for prescription
omega-3 fatty acid products
Dietary supplements are not OTC drugs;
no OTC omega-3 fatty acid or fish oil
products are approved or available
DHA docosahexaenoic acid, EPA eicosapentaenoic acid, LDL-C low-
density lipoprotein cholesterol, OTC over the counter
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6 Discussion
The average patient is exposed to numerous sources of
information about their healthcare, often only remembering
the information that resonates. The concept that a deficiency
of a substance can lead to illness or disease harkens back to the
discovery of vitamins in the 19th century. Subsequently, this
concept has led to purported ‘‘miracle’’ cures and unsubstan-
tiated claims of benefit from thousands of supplement and
nutraceutical manufacturers. It is the role of the clinician to
review data or lack thereof when discussing supplements with
their patients. The indication for use of prescription omega-3
products should be reviewed with the patient along with the
product’s benefits, safety, and the difference between the
prescription product and dietary supplements.
As their name indicates, dietary supplements are only
appropriate to supplement the diet. They contain low doses
of omega-3 fatty acids that are inappropriate for treating
disease. Further, the doses found in omega-3 fatty acid
dietary supplements may not be consistent with those
specified on the label. Lack of regulation and product
quality control may also be responsible for the noted issues
of batch-to-batch variability and presence of contaminating
ingredients in omega-3 fatty acid dietary supplements,
which may also impact proper dosing and potentially
safety. The low doses found in dietary supplements may
not be sufficient for addressing cardiovascular risk, and
professional organizations have been moving away from
recommending these low-dose supplements for cardiovas-
cular protection [76, 77]. However, the triglyceride-low-
ering efficacy of prescription omega-3 fatty acids has been
shown to be dose-dependent [12, 13, 15, 16, 78]. Thus,
patients attempting to administer doses of omega-3 fatty
acid dietary supplements to achieve the level of omega-3
fatty acids in prescription products—and, potentially, their
desired effects—would need to consume a higher number
of capsules than with prescription products. For these
reasons, it is important for primary care physicians to
understand and educate their patients that omega-3 fatty
acid dietary supplements are not approved or intended to
treat disease and should not be substituted for prescription
products. As cost concerns may sometimes lead to inap-
propriate substitution of omega-3 fatty acid dietary sup-
plements for prescription products, it may be worth noting
that patient discount programs exist for some prescription
omega-3 fatty acid products. At the same time, it is equally
important that prescription products containing both DHA
and EPA not be substituted for the purified EPA product
icosapent ethyl, given that DHA may raise LDL-C and
complicate the treatment of patients with dyslipidemia. Per
FDA equivalence codes, pure EPA is not therapeutically
equivalent to DHA-containing products [79].
Although statin therapy significantly reduces cardiovas-
cular events and mortality, elevated triglycerides and
residual cardiovascular risk remain in patients with dys-
lipidemia despite well-controlled LDL-C [80]. Thus, there
is a need for adjunctive therapy to reduce this risk. In the
JELIS study of hypercholesterolemic Japanese patients,
major coronary events were significantly reduced in
patients treated with EPA plus a statin compared with
patients receiving only statin therapy (relative risk reduc-
tion of 19 % in the EPA group, p = 0.011) [81]. More
recently, clinical trials of ezetimibe (IMPROVE-IT [82])
and proprotein convertase subtilisin-kexin type 9 (PCSK9)
inhibitors (OSLER study [83] and ODYSSEY LONG
TERM study [84]) have confirmed or suggested that statin
add-on therapy may be effective in further reducing residual
cardiovascular risk. These studies emphasize that ‘‘lower
LDL-C is better,’’ and that more can be done for statin-
treated patients to address residual cardiovascular risk [85].
Given the multiple beneficial effects of omega-3 fatty
acids, it is reasonable to consider adding a prescription
omega-3 fatty acid to a statin to help address residual
cardiovascular risk. However, previous clinical outcome
studies with products containing omega-3 fatty acids have
produced inconsistent results. Some trials showed signifi-
cant improvements in clinical outcomes [81, 86, 87],
whereas others did not [88–91]. These disappointing results
may be explained in part by insufficient doses of omega-3
fatty acids and/or powering of studies, thus emphasizing
the potential need for high-purity, prescription-strength
dosing and adequately powered studies. Two ongoing
clinical outcome trials are addressing these issues and are
using high-dose prescription omega-3 fatty acids.
REDUCE-IT is comparing icosapent ethyl plus statin ver-
sus placebo plus statin in patients aged C45 years who
have hypertriglyceridemia after receiving statin therapy for
at least 4 weeks, and who have established, or a high risk
of, cardiovascular disease [92]. STRENGTH is comparing
omega-3-carboxylic acids plus statin versus placebo plus
statin in adults with LDL-C \100 mg/dl, high triglyc-
erides, and low HDL after at least 4 weeks of statin ther-
apy, and who are at high risk of a future cardiovascular
event [93]. The results of these trials will help define the
role of prescription omega-3 fatty acid products as add-on
therapy to statins in addressing the residual cardiovascular
risk in patients receiving statin therapy.
7 Conclusions
Prescription omega-3 fatty acid products have proven
safety and lipid-lowering efficacy and can be prescribed
with confidence to patients with elevated triglycerides,
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including those who are already receiving a statin. In
contrast, dietary supplements are not OTC drugs, and
therefore are not required to have a proven safety and
efficacy profile. Dietary supplements are highly variable in
omega-3 fatty acid content and doses between brands, and,
for some products, even between batches. They may also
contain additional ingredients that could counter potential
benefits. Accordingly, they should not be substituted for
prescription products. Similarly, prescription products
containing DHA and EPA should not be substituted for a
purified EPA product, because products that contain DHA
may raise LDL-C, thereby confounding treatment of
patients with dyslipidemia.
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